ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Research Article
Revised

Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis

[version 3; peer review: 2 approved]
PUBLISHED 02 Jun 2021
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

This article is included in the Emerging Diseases and Outbreaks gateway.

This article is included in the Coronavirus (COVID-19) collection.

Abstract

Background: Convalescent plasma (CCP) has been used for treating some infectious diseases; however, the efficacy of CCP in coronavirus disease 2019 (COVID-19) remains controversial. The aim of this research was to assess the efficacy of CCP as an adjunctive treatment in COVID-19 patients.
Methods: Embase, PubMed, Web of Science, Cochrane and MedRix were searched for potentially relevant articles. All included papers were assessed for the quality using modified Jadad scale and Newcastle-Ottawa scale for randomized controlled trial (RCT) and non – RCT, respectively. We used a Q test and Egger test to assess the heterogeneity and publication bias among studies, respectively. Mortality rates between patients treated with standard treatment and standard treatment with CCP were compared using a Z test.
Results: A total of 12 papers consisting of three cross-sectional studies, one prospective study, five retrospective studies, and three RCT studies were included in our analysis. Of them, a total of 1,937 patients treated with CCP and 3,405 patients without CCP were included. The risk of mortality was 1.92-fold higher in patients without CCP compared to patients treated with CCP (OR: 1.92; 95%CI: 1.33, 2.77; p=0.0005). In severe COVID-19 sub-group analysis, we found that patients without CCP had a 1.32 times higher risk of mortality than those treated with CCP (OR: 1.32; 95%CI: 1.09, 1.60; p=0.0040).
Conclusions: CCP, as adjunctive therapy, could reduce the mortality rate among COVID-19 patients.

Keywords

convalescent plasma, passive immunization, COVID-19, mortality, outcomes

Revised Amendments from Version 2

In this new version, we provide the revision of some parts in abstract, introduction, methods, results, discussion, and figure 1. The revision of our new version does not change the main findings of our study.

See the authors' detailed response to the review by Guilherme Welter Wendt

Introduction

The management of coronavirus disease 2019 (COVID-19) remains challenging. While the guideline for the management of COVID-19 has been established,1-3 some reports still reported high mortality rate among COVID-19 patients.4,5 The guideline suggests that several treatments, including antiviral, hydroxychloroquine, steroid, anticoagulation, and other supportive treatments, should be used to treat patients with COVID-19.1-3 However, recent evidence from large scale studies failed to clarify the efficacy of those suggested treatments.6-8 Moreover, the findings from the World Health Organization (WHO) solidarity trials also failed to clarify the benefits of hydroxychloroquine, remdesivir, interferon, and lopinavir in the management of COVID-19.8 Therefore, new approaches to COVID-19 management are required.

Convalescent plasma (CCP), an immunological therapy, is suggested to have promising efficacy for managing several infectious diseases.9 CCP, a strategy of passive immunization, was first introduced by von Behring and Kitasato in 1890. Initially, it was used to treat diphtheria and other infectious diseases such as scarlet fever and pertussis.10 Moreover, due to its good efficacy, this therapy was also used for the management of Ebola, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS).11 In patients with MERS, SARS, and Ebola, the clinical improvement and reduced mortality rate were observed in patients receiving CCP compared to patients without CPP.12 However, the efficacy of CCP against COVID-19 is conflicting. Furthermore, the previous meta-analyses resulted in inconclusive findings due to the lack of structured methodology. Therefore, a holistic meta-analysis is needed to provide insight into the clinical efficacy of CCP for the management of COVID-19.

Methods

Study design

A systematic review and meta-analysis covering the period July 2020 - December 2020 was conducted to assess the efficacy of CCP as an adjunctive treatment in COVID-19 patients. Studies from prominent bibliographic databases were searched, and the protocols followed the guideline from Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA).13

Eligibility criteria

Relevant articles were assessed for inclusion and exclusion criteria before the final analysis. Our analysis included articles with the following criteria: (1) observational or randomized controlled trial studies; (2) providing sufficient data of COVID-19 diagnosis methods; and (3) well-identified methodologies represented with Newcastle-Ottawa Scale (NOS). Case reports, case series, letters to the editor, reviews, commentaries, low method quality, and those with pre-post test comparison were excluded.

Search strategy and data extraction

Relevant studies in four bibliographic databases (Embase, PubMed, Web of Science, and Cochrane) and a preprint database MedRix were searched as of 2 December 2020. The searches limited to English only using Medical Subjects Heading: (“COVID-19” OR “SARS-CoV-2”) AND (“convalescent plasma” OR “serotherapy” OR “hyperimmune globulin therapy” OR “convalescent plasma treatment”). A reference list of the relevant articles was also retrieved for additional references. If a duplicate publication was found, the article with the larger sample size was included. Information of: (1) name of the first author; (2) year of publication; (3) country of origin; (4) sample size of cases and controls, (5) CCP administration, and (6) mortality rate were collected from each article. Search strategy and data extraction were conducted by three independent investigators (MI, AAA & YP) using a pilot form. Disagreements were resolved in group discussions through a consensus approach. Before collecting the data, the investigators performed a discussion to define the study variables and the study protocols, and the understanding among the investigators was assessed using kappa test.

Assessment of the methodology quality

All included papers were assessed for the quality using modified jadad scale for randomized controlled trial (RCT)  and Newcaste-Ottawa scale for non-RCT.14 The quality of the articles was classified as low, moderate, and high quality. Articles with low quality were excluded from our analysis. The assessment was carried out by three independent investigators (MI, AAA & YP), and when there was a discrepancy among the investigators, a discussion was performed with a senior researcher (JKF).

Outcome measure

The primary outcome measure was all causes of mortality among COVID-19 patients treated with and without CCP. The predictor variable was COVID-19 patients treated with CCP. A sub-group analysis was conducted based on the severity of COVID-19 patients treated with CCP (i.e. mild and severe).

Statistical analysis

The association between CCP and the reduction of the risk of mortality among COVID-19 patients was assessed using a Z test. Before assessing the association, the potency of bias and heterogeneity was assessed. To assess the risk of bias, an Egger test was employed to calculate tau-squared, and a p-value of less than 0.05 indicates that the potency of bias was found. A Q test was used to assess the heterogeneity among the included papers. The p-value of less than 0.10 was considered that heterogeneity across the studies was found, and the correlation was therefore determined using a random-effect model; otherwise, a fixed-effect model was employed. All analyses were carried out using Review Manager (Revman Cochrane, London, UK) version 5.3, and the cumulative calculation was presented using a forest plot.

Results

Studies selection and baseline characteristics of the studies

A total of 1,143 papers were identified, and 1,105 papers were excluded because they had irrelevant topics. A total of 38 papers were included for review in full-text, and 26 additional papers were excluded because of review, pre-post test model, commentary, and low-quality papers. In the final process, 12 papers were included in our analysis, consisting of three cross-sectional studies, one prospective study, five retrospective studies, and three RCT studies.15-26 The article selection flowchart is depicted in Figure 1, and the study characteristics are presented in Table 1.

070384b4-d278-486d-83fe-0337bf3ba44d_figure1.gif

Figure 1. A flowchart of study selection in our meta-analysis.

CCP efficacy against COVID-19

A total of 1,937 patients treated with CCP and 3,405 patients without CCP, collected from 12 papers, were included in our analysis. Data suggest that COVID-19 patients without the CCP had a 1.92-fold higher risk of mortality than patients treated with the CCP (OR: 1.92; 95%CI: 1.33, 2.77; p = 0.0005) (Figure 2A). A sub-group analysis among severe COVID-19 patients who were treated with CCP was conducted. This sub-group consisted of nine papers with 1,458 patients treated with CCP and 2,706 patients without CCP. The data revealed a 1.32-fold higher risk of mortality in COVID-19 patients without CCP compared to patients treated with CCP (OR: 1.32; 95%CI: 1.09, 1.60; p=0.0040) (Figure 2B).

070384b4-d278-486d-83fe-0337bf3ba44d_figure2.gif

Figure 2. Forest plot of the association between convalescent plasma and the risk of mortality.

A). All cases (OR: 1.92; 95%CI: 1.33, 2.77; p = 0.0005; p Egger: 0.3620; p Heterogeneity: 0.0600; I-squared: 43.00%). B). Severe COVID-19 (OR: 1.32; 95%CI: 1.09, 1.60; p = 0.0040; p Egger: 0.3790; p Heterogeneity: 0.1200; I-squared: 37.00%).

Table 1. Baseline characteristics of articles included in our meta-analysis.

NameCountryStudy designCitySample sizeCCP volumeRecipientQuality assessment
CCPControl
Abolghassemi et al 2020IranCross‐sectionalMixed11574500 mLMild and severe casesHigh
Altuntas et al 2020TurkeyRetrospectiveMixed888888200 - 600 mLSevere casesHigh
Chen et al 2020ChinaRetrospectiveHangzhou1910200-500 mLSevere casesModerate
Gharbharan et al 2020NetherlandsRCTMixed4343300 mLMild and severe casesModerate
Hegerova et al 2020USARetrospectiveWashington2020200 mLSevere casesHigh
Li et al 2020ChinaRCTWuhan5251100 mLSevere casesModerate
Rasheed et al 2020IraqCross‐sectionalBagdad2128400 mLSevere casesHigh
Salazar et al 2020 (a)USCross‐sectionalMixed321582NAMild and severe casesHigh
Salazar et al 2020 (b)USProspectiveMixed85158NASevere casesHigh
Xia et al 2020ChinaRetrospectiveWuhan1381430200-1200 mLSevere casesHigh
Zeng et al 2020ChinaRetrospectiveHangzhou615300 mLSevere casesHigh

Heterogeneity and potency of bias across the studies

The analysis revealed evidence of heterogeneity in total case of COVID-19. Therefore, a random-effect model was applied to assess the association between CCP and the risk of mortality among COVID-19 patients. In the severe COVID-19 sub-group, we found no heterogeneity, and we used a fixed-effect model to evaluate the correlation. Our analysis using an Egger test found no publication bias in both the total and the severe COVID-19 sub-group (Funnelplot is provided in supplementary file).

Discussion

Our data suggest that CCP treatment associated with a reduction of mortality both in all cases and severe COVID-19 patients. Our current findings are consistent with the results of previous meta-analyses.27-32 The theory underlying the mechanism of CCP in COVID-19 patients remains open to controversy. Briefly, plasma transfer is the potential aspect that bridges the CCP and the reduced risk of mortality in COVID-19 patients. Plasma consists of various immunity components, including antibodies, anti-inflammatory cytokines, clotting and or anti-clotting factors, albumin, and protein C and S.33,34 It is believed that CCP in COVID-19 may modulate the immune response through antiviral effects and has immunomodulatory effects.35 Antiviral effects of CCP may occur through neutralizing antibodies, and it was reported that IgG and IgM anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were the primary isotype antibodies identified from COVID-19 patients treated with CCP.36 This humoral immune response may inhibit protein S of SARS-CoV-2.37 Thereafter, they may exert the protective effects against COVID-19. The immunomodulatory effects of CCP may occur through the neutralization of cytokines and complements.35,38 These effects may inhibit the overactive immune system, including cytokine storm, complement activation, and hypercoagulable state regulation.39 These mechanisms may be responsible for causing clinical improvement of COVID-19 patients. Of them, it was considered that immunoglobulin transfer is the essential factor in modulating the protective effect of CCP.40 In SARS and influenza, it was reported that immunoglobulin transfer plays a vital role in governing clinical improvement.9,11 Moreover, in MERS, the CCP administration with the titers of antibodies 1:80 provided a significant immune response, and the titers of antibodies 1:40 did not provide a similar response.41 Additionally, in Ebola, MERS, and SARS, the antibodies from the CCP may bind to the CD4 binding site on the viral envelope, and therefore may reduce the viral load and the risk of infection of the new cells.42 It was also supported by previous studies that antibody titers from CCP donors also governed the clinical improvement of COVID-19 patients treated with CCP,43,44 suggesting that antibody transfer might influence the outcomes of clinical improvement.

Six systematic-reviews assessing the role of CCP in COVID-19 have been reported (Table 2).27-32 However, they had some significant limitations: (a) the systematic reviews involved had a small sample size while in our current study, we had a relatively larger sample size; (b) some studies did not perform meta-analysis calculations to synthesize the data27,29; (c) some studies included several case reports and case series28,29 in which should be excluded in the meta-analysis13; (d) previous meta-analyses assessed the role of CCP in similar infectious diseases (SARS and influenza), and the results were implemented to the case of COVID-1930,31; and (e) previous meta-analyses performed a mixed calculation where the data of the case vs. control model were combined with the data of pre-post intervention models, which might provide a high risk of bias due to the final effect that might be caused by other interventions.29,32 In the present meta-analysis, we only calculated the model of the case (standard treatment and CCP) vs. control (standard treatment only) and therefore might provide a better correlation.

Table 2. Previous systematic review and meta-analyses and some potential limitations.

Author & yearNumber of studiesSample sizePotential limitations
Bakhtawar et al 202010156
  • - No calculation of data synthesis

  • - Seven case report or case series articles were included

  • - One study comparing the outcome between pre and post convalescent plasma.

Devasenapathy et al 20206431
  • - The case is non COVID-19

Rabelo-da-Ponte et al 2020575
  • - Three case report or case series articles were included

  • - The comparison was pre and post convalescent plasma.

Rajendran et al 20205NA
  • - No calculation of data synthesis

Sarkar et al 202075444
  • - One study comparing the outcome between pre and post convalescent plasma, other studies assessing between convalescent plasma and control (Mixed calculation).

  • - Inappropriate calculation.

Sun et al 2020151879
  • - The case is non COVID-19

In the present study, we emphasized that CCP provided good efficacy to reduce the risk of mortality among COVID-19 patients. Our findings might contribute to better management of COVID-19 patients, particularly to prevent the risk of mortality. It is expected that a medical council should elaborate on the standard procedures of CCP, including the dosage, donor criteria, side effects management, and post-intervention management. Since early administration of CCP provided better clinical outcomes than those with later intervention,45 the appropriate time of CCP administration should be determined, and further studies are warranted.

Several important limitations of this study should be discussed. Some confounding factors that might govern the final outcomes were not controlled, including the immunological status, the dosage of CCP, time of intervention, donor criteria, the titers of antibodies, comorbidities, and transmission area. The majority of the included papers were retrospective studies, and therefore a further meta-analysis of randomized-controlled trials with a bigger sample size might provide a better conclusion.

Conclusion

Administration of the CCP is associated with a lower risk of mortality among COVID-19 patients compared to those without CCP, and this highlights its potency to be used for the treatment of COVID-19. However, studies are warranted to formulate the dosage, time of intervention, donor criteria, and the titers of antibodies to optimize the effects.

Data availability

Underlying data

All data underlying the results are available as part of the article and no additional source data are required.

Reporting guidelines

Figshare: PRISMA checklist for ‘Association between convalescent plasma and the risk of mortality among patients with COVID-19: A meta-analysis’, https://doi.org/10.6084/m9.figshare.13490541.v1.46

Extended data

The supplementary file regarding the funnel plot of our study is provided in Figshare (https://doi.org/10.6084/m9.figshare.14046254.v1).47

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

Comments on this article Comments (0)

Version 3
VERSION 3 PUBLISHED 03 Feb 2021
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Wardhani SO, Fajar JK, Wulandari L et al. Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis [version 3; peer review: 2 approved]. F1000Research 2021, 10:64 (https://doi.org/10.12688/f1000research.36396.3)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 3
VERSION 3
PUBLISHED 02 Jun 2021
Revised
Views
8
Cite
Reviewer Report 04 Jun 2021
Guilherme Welter Wendt, Health Sciences Center, Western Paraná State University (UNIOESTE), Francisco Beltrão, Brazil 
Approved
VIEWS 8
After reading the revised version of the paper, I can see that ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Wendt GW. Reviewer Report For: Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis [version 3; peer review: 2 approved]. F1000Research 2021, 10:64 (https://doi.org/10.5256/f1000research.55951.r86549)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Version 2
VERSION 2
PUBLISHED 08 Mar 2021
Revised
Views
19
Cite
Reviewer Report 29 Mar 2021
Guilherme Welter Wendt, Health Sciences Center, Western Paraná State University (UNIOESTE), Francisco Beltrão, Brazil 
Approved with Reservations
VIEWS 19
The study sought to assess the efficacy of CCP as an adjunctive treatment in COVID-19 patients. The authors are encouraged to:
  1. Correctly report the names of the instruments used (Newcastle-Ottawa, and not Newcaste-ottawa; Jadad scale, and
... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Wendt GW. Reviewer Report For: Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis [version 3; peer review: 2 approved]. F1000Research 2021, 10:64 (https://doi.org/10.5256/f1000research.54795.r81757)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 02 Jun 2021
    Jonny Fajar, Brawijaya Internal Medicine Research Center, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia
    02 Jun 2021
    Author Response
    Response to reviewer comments:
    The study sought to assess the efficacy of CCP as an adjunctive treatment in COVID-19 patients. The authors are encouraged to:

    Correctly report the names ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 02 Jun 2021
    Jonny Fajar, Brawijaya Internal Medicine Research Center, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia
    02 Jun 2021
    Author Response
    Response to reviewer comments:
    The study sought to assess the efficacy of CCP as an adjunctive treatment in COVID-19 patients. The authors are encouraged to:

    Correctly report the names ... Continue reading
Views
16
Cite
Reviewer Report 09 Mar 2021
Morteza Arab-Zozani, Social Determinants of Health Research Center, Birjand University of Medical Sciences, Birjand, Iran 
Approved
VIEWS 16
Thank you for clearly addressing my previous comments. In ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Arab-Zozani M. Reviewer Report For: Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis [version 3; peer review: 2 approved]. F1000Research 2021, 10:64 (https://doi.org/10.5256/f1000research.54795.r81042)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Version 1
VERSION 1
PUBLISHED 03 Feb 2021
Views
33
Cite
Reviewer Report 15 Feb 2021
Morteza Arab-Zozani, Social Determinants of Health Research Center, Birjand University of Medical Sciences, Birjand, Iran 
Not Approved
VIEWS 33
This meta-analysis aimed to investigate the association between convalescent plasma and the risk of mortality among patients with COVID-19. This is a great area of research but, in my opinion, the manuscript needs some major revisions as follows:
... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Arab-Zozani M. Reviewer Report For: Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis [version 3; peer review: 2 approved]. F1000Research 2021, 10:64 (https://doi.org/10.5256/f1000research.39458.r78924)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.

Comments on this article Comments (0)

Version 3
VERSION 3 PUBLISHED 03 Feb 2021
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.